HC Wainwright Has Optimistic Outlook of Nicox Q1 Earnings

Nicox SA (OTCMKTS:NICXF) – Investment analysts at HC Wainwright boosted their Q1 2026 earnings estimates for shares of Nicox in a research note issued to investors on Friday, June 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.03) for the quarter, up from their previous forecast of ($0.04). The consensus estimate for Nicox’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Nicox’s Q2 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at $0.01 EPS.

Nicox Price Performance

Shares of Nicox stock opened at $0.30 on Tuesday. The company has a 50 day moving average price of $0.30 and a 200 day moving average price of $0.30. Nicox has a 52 week low of $0.25 and a 52 week high of $0.30.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.